Published research on Celecoxib
5 peer-reviewed publications on Celecoxib in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.
- Clinical trial
In 2524 patients with stage III colon cancer, three years of celecoxib added to adjuvant FOLFOX did not significantly improve disease-free survival compared with placebo (3-year disease-free survival 76.3% vs 73.4%, hazard ratio 0.89, P = .12).
- Clinical trial
In 312 patients with COX-2-expressing advanced non-small cell lung cancer, the trial was halted for futility and adding celecoxib to chemotherapy showed no significant difference in progression-free survival.
- Clinical trial
In a randomized phase II trial of 134 patients with advanced non-small cell lung cancer, adding celecoxib and/or zileuton to chemotherapy produced no overall survival difference between arms, while a prospectively defined subset analysis suggested better survival with celecoxib in patients with moderate to high COX-2 expression.
- Clinical trial
Celecoxib for the prevention of sporadic colorectal adenomas
In 2035 patients with previously removed adenomas, celecoxib reduced the three-year cumulative incidence of new adenomas (43.2% and 37.5% at the two doses vs 60.7% with placebo) but was associated with an increased risk of cardiovascular events, leading the authors to conclude it could not be routinely recommended for this indication.
- Clinical trial
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
In a double-blind placebo-controlled study of 77 patients with familial adenomatous polyposis, six months of celecoxib at the higher of two doses reduced the mean number of colorectal polyps by 28.0% and polyp burden by 30.7% compared with 4.5% and 4.9% in the placebo group.
Celecoxib in the catalog (specifications, pack sizes, Certificate of Analysis)